We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Incidence of graft-versus-host-disease in Germany: evidence from health care claims data.
- Authors
Scheid, Christof; Kudernatsch, Robert; Eckart, Marie; Libutzki, Berit; Feig, Chiara; Mahlich, Jörg
- Abstract
Objective: Graft-versus-host disease (GvHD) can occur as an immunological response after an allogeneic hematopoietic cell transplantation (allo-HCT). Due to the rarity of the disease, German epidemiological data are scarce. Moreover, not all cases of GvHD are properly documented in daily practice. Against this background, this study aims at providing new estimates on the incidence of GvHD in Germany. Methods: Based on a large German claims database, a retrospective longitudinal analysis was conducted over a 6-year period. Patients were selected that received allo-HCT between 2014 and 2015. Follow up period was 3 years. To adjust the incidence for undocumented cases, steroid prescriptions after an allo-HCT was used as an approximation. Based on both documented and undocumented GvHD patients, incidence rates were calculated for the population of the German statutory health insurance (SHI). Results: Among 4,395,540 eligible database enrollees 3,737,317 were continuously insured. Among them we identified 297 patients who received an allo-HCT between 2014 and 2015. Depending on the extrapolation method, this corresponds to a yearly incidence of 2415–2840 for the SHI population. Of the 297 patients, 134 (i.e., 45.1%) developed a documented GvHD within three years after the transplantation which translates into a yearly incidence of 1125—1300 GvHD patients. Based on the medication regimens, we identified 83 additional patients with an suspected GvHD without a documented diagnosis. Extrapolated to the German SHI population, our estimates suggest that the annual incidence of GvHD, including undocumented cases, could be as high as 1822—2105, which is higher than previously reported. Conclusion: More patients may be affected by GvHD in Germany than reported. Appropriate adjustments need to be made when utilizing administrative data.
- Subjects
GERMANY; HEALTH insurance statistics; GRAFT versus host disease; HOMOGRAFTS; ADRENOCORTICAL hormones; RETROSPECTIVE studies; HEALTH insurance reimbursement; RESEARCH funding; DESCRIPTIVE statistics; KAPLAN-Meier estimator; HEMATOPOIETIC stem cell transplantation; LONGITUDINAL method
- Publication
Journal of Public Health (09431853), 2023, Vol 31, Issue 10, p1609
- ISSN
0943-1853
- Publication type
Article
- DOI
10.1007/s10389-022-01736-w